Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsRoland J. Fuchs, Hans‐Jochem Kolb, Andreas Neubauer et al.|Leukemia|2017Cited by 339
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IVSusanne Saußele, Martin C. Müller, Marie-Paloma Krauß et al.|Blood|2015Cited by 200
Gemtuzumab Ozogamicin in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III StudyRichard F. Schlenk, Hartmut Döhner, Peter Paschka et al.|Journal of Clinical Oncology|2019Cited by 111